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Background: The evolution of drug-resistant parasites is a major hindrance to malaria control, and thus understanding
the behaviour of drug-resistant mutants is of clinical relevance. The study aimed to investigate how resistance against
lumefantrine (LU) and piperaquine (PQ), anti-malarials used as partner drugs in artemisinin-based combination therapy
(ACT), impacts parasite fitness. This is important since resistance to ACT, the first-line anti-malarial regimen is
increasingly being reported.
Methods: The stability of Plasmodium berghei ANKA strain that was previously selected for LU and PQ resistance
was evaluated using the 4-day assay and established infection test in mice. Fitness cost of resistance was determined
by comparing parasites proliferation rates in absence of drug pressure for the drug-exposed parasites between day 4
and 7 post-infection (pi), relative to the wild-type. Statistical analysis of data to compare mean parasitaemia and
growth rates of respective parasite lines was carried out using student’s t-test and one-way analysis of variance,
with significance level set at p<0.05.
Results: During serial passaging in the absence of the drug, the PQ-resistant parasite maintained low growth rates at
day 7 pi (mean parasitaemia, 5.6% ± 2.3) relative to the wild-type (28.4% ± 6.6), translating into a fitness cost of resistance
of 80.3%. Whilst resistance phenotype for PQ was stable, that of LU was transient since after several serial passages in the
absence of drug, the LU-exposed line assumed the growth patterns of the wild-type.
Conclusions: The contrasting behaviour of PQ- and LU-resistance phenotypes support similar findings which indicate
that even for drugs within the same chemical class, resistance-conferred traits may vary on how they influence parasite
fitness and virulence. Resistance-mediating polymorphisms have been associated with less fit malaria parasites. In the
absence of drug pressure in the field, it is therefore likely that the wild-type parasite will out-compete the mutant
form. This implies the possibility of reintroducing a drug previously lost to resistance, after a period of suspended
use. Considering the recent reports of high failure rates associated with ACT, high fitness cost of resistance to PQ
is therefore of clinical relevance as the drug is a partner in ACT.
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Most of the global malaria burden is due to Plasmodium
falciparum and, therefore, many efforts for prevention
and eradication of malaria have focused on this parasite
[1]. Anti-malarial drug resistance poses a very significant
threat in the fight against malaria, making adequate
management of this infectious disease increasingly diffi-
cult [2,3] and thus resulting in high mortality rates.
Development of resistance in malaria is through selec-
tion of variant parasites that are favoured under condi-
tions of drug pressure [4]. Resistance becomes a clinical
problem when the frequency of the resistant variant
threatens the effectiveness of empirical drug therapy.
The level of exposure of the parasite population to the
drug influences the selection of resistant variants [5,6].
Artemisinin and its derivatives are currently deemed the
most potent anti-malarials [7]. They are presently ad-
ministered in combination with at least one other long-
acting anti-malarial, such as lumefantrine (LU), to prolong
their lifespan by reducing the emergence of drug-resistant
parasites [8]. Currently used artemisinin-based combin-
ation therapy (ACT) include artemether-lumefantrine
(ALU, Coartem®), dihydroartemisinin-piperaquine (DHA-
PQ, Artekin®), artesunate-mefloquine, artesunate-sulfadox-
ine-pyrimethamine, artesunate-amodiaquine and artesunate-
pyronaridine [9].
Lumefantrine (LU) and piperaquine (PQ) are both
long-acting anti-malarial drugs currently used as part of
ACT. The terminal elimination half-life of a drug is an
important determinant of the propensity for an anti-
malarial drug to select for resistance. Therefore, the mis-
match between the short-acting artemisinin derivative
and the long-acting partner drug provides selection pres-
sure for emergence of resistant parasites, since one drug
is rapidly eliminated and the other drug persists alone.
This exposes reinfections to sub-therapeutic level of the
slowly-eliminated drug and may be the starting point for
development of tolerance/resistance towards the long-
acting partner [10,11]. The half-life of LU is about 3–5
days [12]. Emerging reports indicate that the use of LU
(aryl amino alcohol) in ALU selects for parasites that are
less susceptible to this drug combination [13-15]. Poly-
morphisms in PfMDR1, particularly the variant N86, and
amplification of the encoding gene (pfmdr1) have been
associated with reduced susceptibility to LU in Africa
and Asia [16,17]. Additionally, parasites with the wild
type copy of PfCRT show reduced susceptibility to LU, as
indicated by both field studies and in vitro assays [18].
Piperaquine (bis-4-aminoquinoline) possesses a pro-
longed half-life of up to 5 weeks. It has the longest ter-
minal elimination half-life of the available artemisinin
partner drugs [19-21]. Consequently, it is rare for new
infections to occur after treatment with dihydroartemi-
sinin-piperaquine DHA-PQ as compared to using otherartemisinin combinations [22-25]. The long half-life of PQ
however may also expose new infections to sub-optimal
drug levels [26] because of its slow elimination, hence
selecting for PQ-resistant parasites.
Studies performed using rodent malaria models to de-
termine the magnitude of selection pressures have
given ambivalent findings. For example, Rosario et al.
[27,28] found a slight advantage of resistance, while
Chawira et al. [29] reported rapid loss of resistance
once drug selection was removed. If drug resistance
does indeed incur a cost on parasite growth rate in the
absence of drugs, it is expected that the virulence and
transmissibility of resistant parasites would also be re-
duced. This is because parasite growth rate and virulence
are positively associated with the parasite’s transmission
rate, and hence its Darwinian fitness [30].
In this study, lines of the ANKA strain of Plasmodium
berghei that had been previously selected for resistance
against LU and PQ were revived and inoculated into mice.
The study was initiated to establish the impact of resistance
on the fitness of LU- and PQ-resistant parasites, in the ab-
sence of the drugs. It would be essential to know the behav-
ior of these parasites, as the two drugs are used as partner
drugs in ACT. The definition of fitness includes an organ-
ism’s ability to survive, reproduce and be transmitted [31].
The fitness cost of resistance, therefore, is the reduced abil-
ity of the resistant population to grow and multiply, with
respect to the ancestor population, in the absence of the se-
lection pressure (in this case anti-malarials) [32,33]. Studies
have confirmed that a reduction in drug use would benefit
the fitter susceptible (without resistance-associated muta-
tions) strains, enabling them to out-compete resistant
strains over time [34-38]. Experimental studies of the costs
imposed by resistance are usually aimed at comparing the
survival and multiplication rates between sensitive and re-
sistant parasites, usually in pair wise competition experi-
ments [35]. Establishing the relations between resistance
and fitness requires experiments on isogenic strains [39]. In
a study assessing the fitness cost paralleled with the
benefit of resistance of a P. falciparum drug resistance
mutation on parasite growth in vitro, results indicated
that mutated parasites grew less in low drug concentra-
tions due to a predominating fitness cost [40,41]. More-
over, studies on the rodent malaria parasites P. berghei
and Plasmodium chabaudi also show that while allow-
ing the resistant parasite to evade the deleterious effects of
the drug, mutations compromise their natural physio-
logical functions [42,43].
It is important to recognize that there are many types
of cost-free and costly forms of parasite resistance. If fit-
ness costs are nevertheless observed in laboratory exper-
iments, it is probable that there will also be clinical
conditions under which the resistance would impose a
fitness burden [44].
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Parasites, hosts and drugs
Lumefantrine and piperaquine-resistant lines of P.
berghei-ANKA were used for this study. The parasites,
maintained in a frozen state (−80°C) at Centre for Trad-
itional Medicine and Drug Research (CTMDR) in Kenya
Medical Research Institute (KEMRI) had been subjected
to selective LU and PQ pressure up to the 73rd and 64th
passages respectively [45]. Wild-type isogenic strains of
P. berghei parasites were revived and independent inocu-
lation was done intraperitoneally (ip) into specific-pathogen-
free (SPF) donor mice. The donor mice were then used for
passaging into groups of experimental male Swiss albino
mice which were 6–8 weeks old weighing 20 ± 2 g that were
random-bred at KEMRI, Nairobi, Kenya, where the study
was conducted. These mice had not been subjected to any
previous experimental procedures. The inoculated mice
were then randomized into groups of five that were housed
in standard plastic cages (layered with woodchip bedding)
per group and maintained in the animal facility. The animals
were fed on commercial rodent pellets and water ad libitum.
Bleeding of donor mice was through the cardiac puncture
on anaethesia with sodium pentobarbital and blood col-
lected into heparinized tubes. All mice that were either
cured or were deemed to have completed their intended use
were euthanized with sodium pentobarbital in the course of
experiments.
The drugs of study, namely LU and PQ were gifts from
Universal Corporation Limited and CTMDR of KEMRI,
respectively. On the day of administration, the drug was
freshly prepared by dissolving it in a vehicle consisting of
70% Tween-80 (d = 1.08 g/ml) and 30% ethanol (d = 0.81 g/
ml) and subsequently diluted 10-fold with double distilled
water (to result in a stock solution of 7% Tween-80 and 3%
ethanol concentration).
Infection of experimental mice
Parasitaemia from donor mice was adjusted downwards
using phosphate saline glucose (PSG) buffer which con-
tained 392 g/L disodium hydrogen phosphate (Na2HPO4),
0.312 g/L sodium dihydrogen phosphate (NaH2PO4), 1.7 g/L
sodium chloride (NaCl) and 10 g/L glucose dissolved
using double distilled water. This solution was then sterilized
by autoclaving at 121°C for 5 minutes then stored at 4°C.
Each of the male albino mice was infected ip with blood
containing approximately 0.5% parasitized red blood cells
(PRBC) in 0.1 ml inoculum. Infection was confirmed by
microscopic estimation of percentage parasitaemia (%P) of
the blood. The day of infection was denoted as day 0 post-
infection (pi), and all experiments were done using these
revived parasites to ensure isogenicity of the parasite. The
inoculated mice were then randomized into groups of five.
The mice were then housed in plastic cages per group
and maintained in the animal facility where they weremonitored twice daily in the course of study. All mice
that were either cured or were deemed to have com-
pleted their intended use were euthanized with sodium
pentobarbital solution (150 mg/kg body weight) in the
course of experiments.
Confirmation of resistance after a period of dormancy
To confirm resistance after cryopreservation, the drug-
exposed and the wild-type revived parasites were subjected
to drug sensitivity studies in a 4-day suppressive test (4DT)
[46] albeit with minor variations [47]. This involved inocu-
lation of 25 mice; 5 mice per group for every dose (total of
four different doses) and one group being the control. The
infection was done ip with infected erythrocytes, on day
zero (D0). The mice were then treated for 4 consecutive
days, at drug doses of 12.5, 25, 50 and 100 mg per kg body
weight for the respective groups. Drug was administered
orally (po) at 4 hrs, 24 hrs, 48 hrs and 72 hrs pi. Thin blood
films were prepared from tail snips on day four (D4) post
infection, and microscopically examined under immersion
oil at × 1000. Every experiment set was done in parallel for
the drug-exposed and drug sensitive parasites (wild-type),
with monitoring being done twice daily. Sodium pentobar-
bital was used to euthanize mice that had been cured of
malaria after treatment, and no recrudescent parasites
observed by day 30 post-infection.
Parasitized cells in 6 fields were counted to give a mean
parasitized cell percentage and percentage parasitaemia
(%P) was calculated as; {Number of parasitized erythrocytes/
(Total number of RBC per field) × 100} [48].
Resistance stability study and serial passage
Parasites were examined for the stability of their drug re-
sponse by weekly passage through mice without drug
pressure [49]. LU-exposed and its wild type isogenic strain
parasites were serially passaged for 22 generations that
lasted over 154 days, while PQ-exposed and the respective
wild-type parasite lines were passaged for 18 generations
(126 days). These parasites were also sub-passaged into
further groups of mice and subjected to in vivo drug sensi-
tivity studies (with a pre-determined dose) to test for their
responses to these drugs (such that for each strain, there
would be both a treated group and a corresponding un-
treated group). Cumulative doses of 30 mg/kg (10 mg/kg/
day) LU and 15 mg/kg (5 mg/kg/day) PQ, administered
po over three days from day 4 pi were used, with daily
monitoring of the experimental mice. This treatment re-
gime had earlier been shown to clear all susceptible para-
sites, without any sign of recrudescence whatsoever.
Stable resistance was defined as the maintenance of the
resistance phenotype all through the passages in the ab-
sence of drug-selection pressure [47,50]. For each drug, at
least two independent experiments were conducted. Drug
efficacy was determined by percentage (%) parasitaemia
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stained thin blood smears under microscope, relative to the
untreated controls. The mice survival rate (%) and drug
curative effect to mice (%) relative to the untreated controls
were also used as a measure of effect of these drugs on the
infected mice. Mice that showed parasites on day 4 pi, but
were aparasitaemic (in this case, up to 10 fields were micro-
scopically examined and no infected erythrocytes detected)
on subsequent days post-treatment up to day 30 pi were
considered cured [51]. Percentage (%) parasitaemia sup-
pression for the drugs was calculated as: 100 − {(mean para-
sitaemia treated/mean parasitaemia control) × 100} [52].
Fitness cost of resistance
The parasites used in this study were isogenic (a sensi-
tive wild-type clone and a resistant mutant derived from
it) differing only on their susceptibility to the drug. Con-
sidering their isogenicity, their growth rate was used as a
measure of fitness [4,43,53]. Parasite growth rate be-
tween day 4 and 7 pi in the course of serial passaging in
the absence of drug was used to assess the parasites pro-
liferation rates for the LU and PQ-exposed parasites
relative to their wild-type counterpart, and thus their fit-
ness. The percentage loss of fitness of the mutant para-
sites relative to the wild-type was expressed as: 100 –
{(mean parasitaemia mutant/mean parasitaemia wild-
type) × 100} [54]. Percentage parasitaemia was recorded
in Microsoft Excel® 2010 and expressed as the mean ±
standard error of mean. ED50 (Effective dose that re-
duces parasitaemia by 50%) was determined using linear
regression equation in Excel, while statistical analysis of
data to compare mean parasitaemia and growth rates of
the appropriate parasite lines was carried out using stu-
dent’s t-test and one-way analysis of variance (ANOVA).Figure 1 Established infection drug sensitivity tests for lumefantrine
mice. Treatment was done using a dose of 10 mg/kg LU and 5 mg/kg PQ
from day 4 post-infection.Statistical significance was defined for an overall error at
0.05 level (95% confidence interval).Ethics statement
Permission to use mice was granted by the Animal
Care and Use Committee (ACUC), KEMRI, where all
animal experiments were conducted after the research
protocol approval by Mount Kenya University Ethics
Research Committee (Permit Number: MKU/ERC/0004/
2013) which is accredited by the National Council for
Science, Technology and Innovation (NACOSTI). All ef-
forts were made to minimize animal suffering, and animals
were euthanized using 150 mg/kg body weight sodium
pentobarbital solution injected intraperitoneally after their
intended use. The euthanized mice were autoclaved in
biohazard disposable bags at 121°C for 15 minutes be-
fore incineration to destroy all infectious agents and to
avoid environmental contamination.Results
Lumefantrine and piperaquine-resistance was not lost
with dormancy
Parasitaemia patterns obtained after mice infected with
lumefantrine (LU) or piperaquine (PQ) resistant lines
were orally treated with either LU or PQ indicated that
the resistance phenotype for both had not been lost with
dormancy, as shown in Figure 1. Upon revival of the
parasites in mice, initial drug susceptibility tests using
the 4DT (4-day suppressive test) and established infec-
tion test confirmed high levels of resistance, indicating
that these drug-exposed parasites did lose their resist-
ance with dormancy.(LU)- and piperaquine (PQ)-exposed parasites at passage 2 in
respectively, administered orally over 3 days consecutively starting
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Lumefantrine resistance phenotype was evident over the
first 16 passages in the absence of drug pressure, since
mice infected with LU-resistant parasites and treated with
LU continued show blood stage malaria parasites which
not only persisted but also grew with greater robustness,
compared to the sensitive strain. Moreover, these parasites
were highly resistant as a dose of up to 100 mg/kg only
slightly reduced the parasitaemia whereas 5 mg/kg dose
cleared the wild strain in an established infection study.
Most of the untreated control mice infected with LU-
exposed and wild-type parasite lines died by day 8 pi with
increasing parasitaemia.
Interestingly, from passages 17–22, the LU-treated mice
infected with either the LU-exposed or wild-type parasites
showed similar susceptibility to LU, where no parasites
could be observed under the microscope at days 7 and 10
pi, and without any recrudescent parasites even by D30 pi
(Figure 2). Effective doses that reduced parasitemia by
50% (ED50) values were useful in estimating the level of
resistance of the drug-exposed parasites and were assessed
at the beginning and end of study, as shown in Table 1.
To determine the ED50, two independent experiments
were performed and mean parasitaemia of mice per group
was calculated, and used to estimate percentage chemo-
suppression, relative to the untreated controls. A dose–re-
sponse curve was then plotted and using a linear regres-
sion line (Microsoft Excel® 2010), the drug concentrations
at which 50% of suppression of parasitaemia was achieved
determined. At the beginning of the study (passage 2), the
ED50 was determined as 93.31 mg/kg. However, at passage
17, there was complete loss of LU-resistance since the
ED50 value of 1.83 mg/kg was obtained, which implies that
in the course of serial passaging, these parasites may haveFigure 2 Sensitivity of lumefantrine (LU)-exposed Plasmodium berghe
LU-exposed parasites by D7 post-infection (pi), confirming loss of resistanlost resistance. This ED50 value was maintained over the
next drug free passages (up to passage 22). Moreover, the
observation that LU-exposed line assumed the patterns of
its wild-type counterpart overtime indicates instability of
this resistance.
Piperaquine resistance is stable
Mice infected with wild-type parasites and treated with
PQ showed complete susceptibility to PQ, since no para-
sites could be observed under the microscope at days 7
and 10 pi, without any recrudescent parasites appearing
even by D30 pi. Mice infected with PQ-resistant parasite
and treated with PQ showed similar (P > 0.05) patterns
at passages 2 (beginning of study), 10 and 18 (end of
study) in which only a slight non-significant (P > 0.05)
decline in parasitaemia at D7 pi was observed relative
to D4 pi, followed by gradual increase in parasitaemia
on subsequent days. The ED50 at the 18
th passage was
81.02 mg/kg bw which was comparable to that at the
beginning of the study (85.97 mg/kg, P > 0.05), and thus
high indices of resistance (I50 values of 66.13 and 66.35
at passage 2 and 18, respectively) (Table 1), confirming
that PQ-resistance was stable. Figure 3 shows the drug
sensitivity patterns for PQ-exposed parasites at pas-
sages 2, 10 and 18.
Lumefantrine resistance does not impose a fitness cost to
the parasite
Comparison of parasitaemia at days 4 and 7 pi between LU-
exposed and wild-type parasites lines in mice over 22 pas-
sages in the absence of drug revealed that previous exposure
of the parasite to LU had influenced its characteristics. In
the stability study, it was observed that LU-exposed parasite
was growing at a different rate compared to LU-sensitivei ANKA to LU at passage 17. A dose of 10 mg/kg/day cleared
ce. No recrudescence was observed even by D30 pi.
Table 1 Response of drug-exposed Plasmodium berghei ANKA strain to piperaquine and lumefantrine
Drugs used to treat mice infected with lumefantrine- and piperaquine-exposed P. berghei ANKA
















1.67a 93.31 1.83 1.30 85.97 81.06
I50
c 1.00 55.87 1.09 1.00 66.13 62.35
Results are presented as effective doses that reduce parasitaemia by 50% (ED50) and as 50% indices of resistance (I50).
Drug responses (50% effective doses, ED50s) as well the respective 50% indices of resistance (I50s) of lumefantrine (LU)- and piperaquine (PQ)-exposed Plasmodium
berghei ANKA in mice at initial stages of passaging (passage 2) and at the end of passaging (passage 22 and 18 for LU-exposed and PQ-exposed respectively).
aThe ED50 of the parent strain from which both LU- and PQ-exposed strains were generated is included for comparison.
bData are presented as effective doses
that reduced parasitemia by 50% (ED50).
cIndices of resistance (I50, defined as the ratio of the ED50 of the resistant line to that of the parent strain) confirm that
artificially-induced PQ-resistance is stable.
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lower growth rates between passages 1–3 (mean parasit-
aemia of 2.8 ± 1.5) relative to the wild-type parasite
(mean parasitaemia of 4.7 ± 0.3), albeit not significantly
different (P > 0.05). Interestingly, for the next serial pas-
sages, the LU-exposed parasite line had significantly
(P = 0.01) higher parasitaemia than the wild-type para-
site, implying that the resistant parasite assumed a faster
growth rate from passage 4 onwards. Its mean parasit-
aemia of 9.98% ± 3.4 (over the 22 passages) at D4 pi was
significantly different (P < 0.05) from the mean parasit-
aemia of LUS (7.72% ±1.9), indicating a faster growth rate
than the latter at day 4pi. At passage 17 however, the para-
sitaemia patterns for the two strains were not significantly
different (P > 0.05) and descended to the levels of the wildFigure 3 Parasitaemia patterns for wild-type and piperaquine (PQ)-re
passages 2, 10 and 18. The mice were treated once daily for 3 days with
mirror each other (2, 10 and 18), confirming that the PQ-resistance is stable
type infected mice, up to D30 post-infection.type, maintaining an almost similar growth pattern for the
subsequent passages. During early passages, mice infected
with LU-exposed parasite had longer survival relative to
the wild-type parasite infected mice. In later passages
however, their survival of up to D10 pi was similar to that
of mice infected with LU-sensitive parasites. Figure 4
shows different trends observed in the parasitaemia pat-
terns for wild-type and LU-exposed parasites.
Piperaquine resistance imposes a fitness cost on the
resistant line
Parallel serial passaging of PQ-resistant and –sensitive
parasite lines showed that the resistant parasite had a
much slower growth rate compared to the sensitive line as
shown in Figure 5. The PQR strain showed significantlysistant Plasmodium berghei ANKA parasites treated with PQ at
PQ (15 mg/kg cumulative dose) at every two passages. The patterns
. No recrudescent parasites were observed following treatment of wild
Figure 4 Growth patterns for wild-type (LUS) and lumefantrine-exposed (LUR) Plasmodium berghei ANKA parasites between D4 and D7
post-infection (pi) in the absence of drug. The parasitaemias were assessed at days 4 and 7 pi in the course of serial passaging of the
respective parasite lines in mice for up to 22 serial passages in the absence of drug. The LUR mean parasitaemia at D4 pi was slightly higher than
that of LUS, though there was no significant difference in percentage parasitaemia by D7 pi.
Figure 5 Growth patterns for wild-type and piperaquine-resistant Plasmodium berghei ANKA parasites between D4 and D7 post-infection
(pi) in the absence of drug. The parasitaemias were assessed at days 4 and 7 pi in the course of serial passaging of the respective parasite lines in
mice for up to 18 serial passages in the absence of drug. The mean parasitaemias for the two parasite lines were different even at day 4 pi. At day 7
pi, the wild-type parasite had five times higher parasitaemia than the PQ-resistant parasite. It was also observed that untreated mice infected with the
PQ-resistant parasite had slightly longer survival (>25 days) which was statistically significant (P < 0.05) relative to the wild-type and the
LU-exposed parasite-infected mice with survival of up to 10 days. All the animals succumbed to malaria infection in the absence of treatment, with the
mice infected with sensitive parasites (wild-type, PQS) dying by day 10 post-infection and those infected with resistant parasites (PQR) dying by day
28 post-infection.
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parasitaemia = 5.6 ± 2.3) relative to the wild-type parasite
(28.4 ± 6.6) at D7 pi. These differences in parasitaemia
translate into a five-fold faster growth rate for the wild-
type parasite by D7 pi, and an overall asexual stage resist-
ance cost of fitness of 80.3% for the PQ-resistant line.
Discussion
Alterations that render an organism resistant to a drug are
likely to be associated with a loss of fitness. To further the
knowledge on the impact of resistance on parasite fitness,
rodent malaria parasites that had been previously sub-
jected to selective drug pressure using LU (aminoalcohol-
fluorene derivative) and PQ (4-aminoquinoline), two long-
acting anti-malarials currently used in combination with
artemisinin derivatives, were investigated. Drug sensitivity
tests on revived LU and PQ-exposed parasites confirmed
that resistance was not lost even after cryopreservation for
over four years. Some studies have revealed that parasites
can revert to the sensitive phenotype after cryopreservation
[55]. For example, a study by Hunt et al. [55] confirmed re-
duced susceptibility to artemisinin, but the phenotype was
not stable. Deviations in resistance stability and fitness
costs of resistance may occur due to differences in mecha-
nisms of resistance for different drugs. Other mechanisms
of sustaining resistance in these parasites could have also
been involved, including transient changes in gene expres-
sion, which may account for the loss of resistance after
cryopreservation of parasites observed by Hunt and col-
leagues. The fact that these parasites revived and had high
indices of resistance (I50, defined as the ratio of the ED50 of
the resistant line to that of the parent strain) confirmed the
stability of this artificially-induced resistance.
When both LU- and PQ-exposed parasite lines were
serially passaged in the absence of the drug, it was ob-
served that the effect of drug-exposure impacted their
growth and multiplication capacities differently. In this
study, results point out that at the initial phases (pas-
sages 1–3) of serial passaging, the LU exposed parasites
multiplied at a slower rate. However, this trend changed
from passage 4 when the growth rate of LUR was much
faster, having the mice die by day 10 at passage 5 and
beyond, (with increasing parasitaemia), whereas initially
they could survive even up to Day 28 (passage 1). The
differences observed between LU-exposed parasites and
their wild-type isogenic strain could have been due to
epigenetic modification. These include the heritable
changes in gene function that occur without a change in
the nucleotide sequence [56]. Epigenetic factors include
DNA methylations, histone modifications, and micro-
RNAs, and may explain how cells with identical DNA
can differentiate into diverse cell types with different
phenotypes [57]. Epigenetic effects may have been in-
volved in that; the previous continuous exposure of theparasites to LU might have triggered epigenetic adapta-
tions. These probably increased the parasites’ tolerance to
the drug, but were manifested only in a transient manner
and were consequently lost after stopping drug treatment
and during passaging. The data suggests that resistance to
LU seems to have no negative impact on the growth of
these parasites, in the absence of drug pressure.
It is probable that for LU, the prevalent strains may have
lost the mutant gene(s), or unrelated, susceptible strains
may have coincidentally replaced the former strains [31].
Theoretically, the latter is expected to be much more
common, since the accumulation of compensatory muta-
tions is one of the barriers to genetic reversions [31,58].
Resistance might have been due to genetic mutations that
were not sustainable by the parasites and therefore lost in
the absence of treatment, as confirmed at passage 17.
Since a fixed dose (10 mg/kg) was in use during the sensi-
tivity tests, it is feasible that loss of resistance might have
occurred gradually and was only noted when this dose
cleared even the LU-exposed parasites. This is because
supplementary studies at the initial passaging phases
showed that even a dose of up to 100 mg/kg for 3 days
could only suppress but not clear these parasites. This was
moreover emphasized by the fact that the ED50 at the be-
ginning of the study for the LUR parasites was found to
be 93.31 mg/kg. A study by Kiboi et al. [45] determined
the ED50 for the sensitive parasites to be 1.67 mg/kg of
LU. This therefore corresponds to an index of resistance
of 55.87, confirming a high level of resistance. The fact
that the ED50 had dropped to almost the level of the
sensitive parasites by passage 17 confirms sensitivity of
the parasites to LU.
For the PQ-exposed parasites, results clearly indicated
that there was a fitness disadvantage on the resistant line.
There was a significant difference (P < 0.05) in parasit-
aemia between the two lines even by day 4 pi. The PQS
had a similar pattern to the LUS, with no significant differ-
ence in parasitaemia (P > 0.05) recognized despite the fact
that the experiments were set at different times. This
would however be expected as they were both sensitive
strains, and also authenticates the reproducibility of the
results observed. Observations made on PQR correspond
to several previous studies which indicate that mutations
associated with drug resistance confer a fitness cost. This
suggests that they might disappear by reducing the vol-
ume of drug pressure, assenting that resistant forms of an
organism are likely to be less fit than their wild-type sensi-
tive strains, in the absence of selection [44,59-63]. Genetic
hitch-hiking, which occurs especially among resistant par-
asites in the field is a detriment to them as it restricts their
variability [64,65], further explaining why their frequency
diminishes when active drug selection declines.
It is elucidated that the lack of expression of pfmrp
leads to a fitness cost of the parasite in in vitro malaria
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to an impaired transport of toxic metabolites out of the
parasite [65]. In the event that resistance to PQ is associ-
ated with an anomaly in pfmrp, then this would explain
the fitness costs observed in the PQ resistant line. The
mechanism of PQ resistance is however still under in-
vestigation. Despite its chemical similarity to CQ, Somé
et al. [66] confirmed that the polymorphisms selected
for by PQ were different from those by CQ or atova-
quone (AQ), suggesting different mechanisms of resist-
ance. PQ results confirm the theory of cost of resistance,
having a five-fold faster growth rate for the wild-type
parasite by D7 pi, and an overall resistance cost of fitness
of 80.3% for the PQ-resistant line.
This study has confirmed that significant fitness costs
are associated with PQ resistance and that the selective
benefit acquired by becoming drug resistant is in some
way biologically costly to the altered parasite [67]. It
should however be noted that the strength of the fitness
cost may vary between strains [36,68,69]. Furthermore, re-
sults from in vitro culture experiments or resistance muta-
tions obtained in a laboratory in vivo system (P. berghei)
may not be a clear representative of natural populations of
P. falciparum [70] and therefore further studies on P. fal-
ciparum still ought to be performed. However, if these
results are general across parasite genotypes and species,
this has significance especially for mutant parasites result-
ing from continued population-wide exposure to drugs.
This laboratory-based study provides information on the
effect of resistance mutation on parasite fitness, and could
certainly be extended to suggest field conditions more ap-
propriately. For instance, by crossing genetically diverse
transmissible P. berghei isolates in the laboratory under a
range of drug treatments through successive generations
[71]. An understanding of the physiological basis of fitness
and genetic changes associated with resistance to a par-
ticular anti-malarial drug may lead to estimation of associ-
ated cost and potential weaknesses in resistant parasites,
which can then be managed more effectively [33,72].
It was concluded that significant fitness costs are associ-
ated with PQ-resistance and this knowledge could help in
establishing strategies for treatment of resistant malaria
parasites. Since the work done was in vivo and thus based
on observing phenotypic characteristics, a molecular ap-
proach to determine the actual genes, mutations or epigen-
etic factors that are involved in resistance and fitness costs
due to LU and PQ still ought to be performed. Moreover,
properly structured and precise laboratory studies should
be performed using anti-malarial drugs such as CQ and
sulfadoxine-pyrimethamine (SP) which have been with-
drawn from use in Kenya for several years now. This will
help establish possibility of future re-introduction of the
drugs if true resistance imposes a fitness cost. In several
countries such as Malawi where CQ use was suspendedearly enough because of widespread resistance, sensitive P.
falciparum strains have re-emerged and are expanding
[36,73]. Considering that numerous deaths from malaria
are still reported in Africa, where the greatest transmission
intensity occurs, this presents a ray hope in the efforts to
control malaria. Future reintroduction of a drug for the
management of malaria should be planned bearing in mind
evolution of drug resistance, with the aim of identifying
combinations that could deter the re-emergence of resist-
ance. In malaria-endemic countries with semi-immune
host populations, such as Kenya, even a partial resump-
tion of drug sensitivity after loss to resistance, may
positively impact public health.
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